Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOAL study of inhaled levofloxacin plus antibiotics for prevention of COPD exacerbations
NL-OMON50113Phase 4Withdrawn
- Sponsor
- Amphia Ziekenhuis
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of levofloxacin in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Amphia Ziekenhuis. Primary endpoints: Time to next exacerbation and Mean number of exacerbations in 6-month follow-up. Planned start Feb 2021; status: withdrawn.
02
Drugs
levofloxacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON50113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50113.